
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is making significant strides in their pipeline with the development of next-generation ADCs targeting Folate receptor alpha (FRα), as well as new drugs targeting IRAK4 and CD19 receptors in immunology and neuroscience. With strong sales growth for their existing immunology drugs, such as Rinvoq and Humira, and the recent acquisition of Allergan's aesthetic products, AbbVie is poised for long-term success. Additionally, the company has a diverse range of potential catalysts in upcoming years, including multiple Phase 3 data readouts and FDA decisions.
Bears say
AbbVie is performing well in the current quarter with total net revenues and adjusted EPS exceeding expectations, driven by key drivers such as Skyrizi, Rinvoq, Botox, Ubrelvy, Vraylar, and Venclexta. However, concerns include potential competition and pricing risks for Skyrizi and Rinvoq, as well as potential future pricing headwinds and clinical risks in the immunology field. Additionally, AbbVie's low tax rate and potential changes in tariffs or taxes could impact its performance as a company.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares